Juno Therapeutics (JUNO) – Analyst EPS View
-
Juno Therapeutics (JUNO) PT Raised to $66 at Wells Fargo on ASH Update: 'TRANSCEND Data Analysis Suggests Importance Of Tumor Burden'
-
Juno Therapeutics (JUNO) PT Lowered to $30 at Citi; 'DLBCL pivotal to start in 2017'
-
-
-
-
-
Back to JUNO Stock Lookup